Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.
2 reports, 1 independent
Updated Jul 25
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Also in this story
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.
The entities involved
-
Verve Therapeutics
American pharmaceutical company
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
- The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market.
- Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
Coverage
Newest first; wire copies grouped- PR NewswireLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
- Unknown outlet